Virologic suppression and CD4 cell count recovery after
initiation of raltegravir- or efavirenz- containing HIV treatment regimens.
Edwards JK, Cole SR, Hall HI,
et al
AIDS. 2017 Nov
2
Abstract
HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz
Reduces Neural Stem Cell Proliferation in Vitro and in Vivo.
Jin J, Grimmig B, Izzo J, Brown LAM, et al
Cell Transplant.
2016 Nov;25(11):
Abstract
HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz
Reduces Neural Stem Cell Proliferation in Vitro and in Vivo.
Jin J, Grimmig B, Izzo J, Brown LAM, et al
Cell
Transplant. 2016
Nov;25(11)
:Abstract
Efavirenz or nevirapine in three-drug combination therapy with two
nucleoside or nucleotide-reverse transcriptase inhibitors for initial
treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L, Mursleen S, Irlam JH,
et al
Cochrane Database Syst Rev.
2016 Dec 10;12:CD004246
Abstract
Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose
combination for paediatric patients.
Bouazza N, Cressey TR, Foissac F,
et
al
J Antimicrob Chemother. 2016
Oct 24.
Abstract
Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in
HIV-infected patients.
Serrano-Villar S, Zhou Y, Rodgers AJ, Moreno S.
J Antimicrob Chemother.
2016 Sep 21
Abstract
FULL-TEXT ARTICLE
Complete dataset
for 2-treatment, 2-sequence, 2-period efavirenz bioequivalence study conducted
with nightly dosing.
Ibarra M, Magallanes L, Lorier M, et al
Data Brief. 2016 Mar
15;7:751-4.
Paper
FULL-TEXT ARTICLE
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity
in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized
Trial.
Serrano-Villar S, Sainz T, Ma ZM, et al
PLoS Pathog. 2016 Jan 21;12(1):e1005381|
Paper
Efavirenz (EFV) but not Atazanavir/ritonavir (ATV/r) Significantly Reduces
Atovaquone Concentrations in HIV-infected Subjects.
Calderón MM, Penzak SR, Pau AK,,et a
lClin
Infect Dis. 2016 Jan 20.
Abstract
FULL-TEXT ARTICLE
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A
Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kryst J, Kawalec P, Pilc A.
et al
PLoS One. 2015 May
1;10(5):e0124279
Paper
FULL-TEXT ARTICLE
Prospective Immune Dynamics during the First 24 Weeks of Efavirenz
Based-Antiretroviral Therapy in HIV-1-Infected Subjects, According to CD4+
T-Cell Counts at Presentation: The IMMUNEF Clinical Trial.
Soria A, Trabattoni D, Squillace N, et al
PLoS One. 2015 Feb
11;10(2):e0117118.
Paper
Use of efavirenz or atazanavir/ritonavir is associated with
better clinical outcomes of HAART compared to other protease inhibitors: routine
evidence from the Italian MASTER Cohort.
Postorino MC, Prosperi M, Quiros-Roldan E, et al
Clin Microbiol Infect.
2014 Nov 11. pii: S1198-743X(14)00088-3.
Abstract
Week 48 results of a Phase IV trial of etravirine with antiretrovirals other
than darunavir/ritonavir in HIV-1-infected treatment-experienced adults.
Arathoon E, Bhorat A, Silaghi R, et al
J Int AIDS Soc.
2014 Nov 2;17(4 Suppl 3):19783
Abstract
Virologic and immunologic responses in treatment-naive patients
to ritonavir-boosted atazanavir or efavirenz with a common backbone.
Wang Q, Young J, Bernasconi E, Vernazza P, et al
HIV Clin Trials. 2014 May-Jun;15(3):92-103.
Abstract
Comparing the efficacy of efavirenz and boosted lopinavir using viremia
copy-years.
Lima VD, Sierra-Madero J, Wu Z,
et
a;
J Int AIDS Soc. 2014 May 6;17(1):18617.
Abstract
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected,
antiretroviral-naive adults (ENCORE1): a randomised, double-blind,
placebo-controlled, non-inferiority trial.
ENCORE1 Study Group.
Lancet. 2014 Feb 7. pii:
S0140-6736(13)62187-X.
Abstract
Outcomes In Older Versus Younger Patients Over 96 Weeks In
Hiv-1-Infected Patients Treated With Rilpivirine Or Efavirenz In Echo And Thrive
Ryan R, Dayaram YK,
Schaible D, et al
Curr HIV Res. 2014 Jan 28
Abstract
Effectiveness of efavirenz compared with ritonavir-boosted
protease inhibitor-based regimens as initial therapy for patients with plasma
HIV-1 RNA above 100,000 copies/ml.
Imaz A, Llibre JM,
Navarro J, et al
Antivir Ther. 2014 Jan 23.
Abstract
FULL=TEXT ARTICLE
Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz
Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort
Study in Two Sub-Saharan Africa Populations.
Ngaimisi E, Habtewold A, Minzi O, et al
PLoS One.
2013 Jul 5;8(7):e67946.
Paper
Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected
Persons in
Routine Clinical Care.
Taniguchi T, Grubb JR, Nurutdinova D,
et al
J Int Assoc Physicians AIDS Care (Chic).
2012
Abstract
Rilpivirine. First-line treatment of
HIV infection: efavirenz is better documented.
[No authors listed]
Prescrire Int. 2012 Nov;21(132):262-5
Abstract
FULL-TEXT ARTICLE
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of
HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings.
Campbell TB, Smeaton LM, Kumarasamy N,
et al
PLoS Med. 2012 Aug;9(8):e1001290.
Paper
Long term outcomes of nevirapine containing antiretroviral therapy at a center
in Thailand.
Htun WL, Bowonwatanuwong C, Phonrat B, Pitisuttithum P.
Southeast Asian J Trop Med Public Health. 2012
Jul;43(4):860-70.
Abstract |
General
Reports
Treatment
Strategies
Drug
Failure
Main
New/Newsworthy
Documents identified with this icon are in Portable Document Format (PDF)
and require the
